An experimental study of ovarian cancer imaging and therapy by paclitaxel-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound
- Maternal-Fetal Medicine Institute, Bao'an Maternity and Child Health Hospital, Jinan University, Shenzhen, 518100 (China)
- Maternity and Child Health Hospital, Wuxi, 214000 (China)
- Shenzhen Children's Hospital, Shenzhen, 518100 (China)
Highlights: • PTX-anti-LHRHR-PTNPs is expected to become a new type of ultrasound contrast agent. • LIFU can enhance the efficiency of PTX-anti-LHRHR-PTNPs. • For ovarian cancer, PTX-anti-LHRHR-PTNPs has a good therapeutic effect. Drug-loaded phase-transformation lipid nanoparticles (NPs) combined with low-intensity focused ultrasound (LIFU) for ultrasound molecular imaging and therapy, which is a very promising drug carrier and can provide both physical and chemical therapeutics, simultaneously. We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells. Thereby, the special drug carrier improved the therapeutic effect and reduced toxic and side effects, maximized the protection of normal tissues and minimized adverse reactions. On the other hand, PTX-anti-LHRHR-PTNPs can be targeted to focus after being injected intravenously and remain in the tumor target tissue for a long time. At the same time, liquid-gas phase-transformation can occur under LIFU triggering, resulting in more ideal and sustained ultrasound imaging effects. Then acoustic contrast agent is used to develop the molecular level of ultrasound scattering, so as to evaluate the diseased tissue from the molecular level.
- OSTI ID:
- 23103534
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 504, Issue 1; Other Information: Copyright (c) 2018 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis
The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer